Merck & Co., Inc.

▲ Bull Case

• ◆QLEX converts 35-45% of IV pembrolizumab patients by FY2028 due to SC administration advantage, preserving $10-12B of Keytruda revenue that would otherwise be lost to biosimilar competition; combined Keytruda/QLEX revenue stays above $30B in 2030.
• ◆WINREVAIR reaches $6-7B peak by FY2029 following HYPERION WHO Class II PAH label expansion and full EU/Japan rollout; at $6.5B peak with 50% EBITDA margin generates $3.25B incremental EBITDA, equivalent to building a new mid-cap pharma company on top of existing base.
• ◆MK-7240 (TL1A/IBD) Phase 3 GARNET readout succeeds in 2027; positions Merck as successor to immunology's standard of care with $5-10B peak potential; combined with QLEX/WINREVAIR success drives Non-GAAP EPS to $10-12 by 2030 and stock to $175-210 at 17-18x multiple.

▼ Bear Case

• ◆QLEX stalls at 12-18% conversion by FY2028 due to formulary resistance or pricing friction; without QLEX covering the SC position, all IV pembrolizumab patients become exposed to biosimilar substitution; combined Keytruda/QLEX revenue falls to $18-22B by FY2030 vs. $31.7B FY2025A, a $10B+ revenue loss.
• ◆IRA Keytruda price cut settles at 40-50% consistent with CMS's actual historical negotiating pattern (Januvia -79%, Farxiga -68%, Eliquis -56%); political incentive to maximize savings on the biggest drug in Medicare's portfolio is extreme; a 45% cut adds $4-5B of additional annual revenue loss beyond base case assumptions.
• ◆Pipeline execution failure on multiple fronts: Cidara (MK-1406 influenza) fails Phase 3, Terns CML asset fails to differentiate in crowded market, Ohtuvayre COPD penetration disappoints; $25-30B of deployed M&A capital impaired or below WACC; WINREVAIR alone cannot offset cliff; Non-GAAP EPS troughs at $5-6.50 and stock trades to $50-70.

“The central debate is whether IRA price cut settles at 25-35% or 40-50%. Bull consensus (10 Buy analysts, avg. target $130) assumes 25-35%, citing Keytruda's biologic complexity and QLEX as a negotiating lever. This produces a $5-7B annual revenue impact from 2029 — painful but survivable. Bear view argues CMS historical track record on all negotiated drugs shows 56%+ cuts; biologics are not protected; Keytruda being the single most expensive drug creates structural incentive for 40-50%+ cuts. This is a $5-8B annual revenue question (roughly $2-3 per share of Non-GAAP EPS) that will not be resolved until CMS announcement in 2027. The market at $112 is pricing between the two views, which is rational given genuine uncertainty. This debate suppresses the multiple and creates wide valuation range ($55-210).”

• ◆Q2 2026 earnings (Late July) — QLEX conversion rate disclosure; most critical 2026 data point for thesis validation
• ◆WINREVAIR HYPERION label expansion (September 2026) — WHO Class II PAH approval could open 2-3x addressable market; single largest positive catalyst in next 6 months
• ◆MK-7240 (TL1A/IBD) Phase 3 GARNET readout (2027) — binary outcome removes/validates $5-10B of pipeline option value
• ◆IRA Keytruda negotiated price announcement (2027) — $5-8B annual revenue question that structurally suppresses current multiple
• ◆Keytruda QLEX >20% conversion milestone (2027) — validates conversion trajectory toward bull case assumptions
• ◆First biosimilar IV pembrolizumab approval (2028) — initiates revenue erosion phase; timing and adoption critical

• ◆IRA price cut at 40-50% vs. base case 25-35% — CMS historical track record (Januvia -79%, Farxiga -68%) suggests higher cuts are base-rate probable; adds $4-5B annual revenue loss
• ◆QLEX conversion stalls below 15% by FY2028 — Q1 2026 starting point of 1.6% leaves no safety margin; thesis depends on 30-35% conversion to offset IV biosimilar exposure
• ◆Pipeline execution failure (Cidara + Terns + Ohtuvayre) — $25-30B deployed across three concurrent speculative deals in competitive markets; one or two failures materially impair recovery narrative
• ◆China Gardasil structural impairment — if China HPV market permanently reduced to $3-4B vs. $8-9B peak, requires $5B annual replacement from other sources
• ◆Net debt ($44B) limits defensive M&A flexibility at cliff trough — if cliff is harder than expected, balance sheet capacity to make additional acquisitions is constrained